Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein.
BACKGROUND
Current Ebola virus (EBOV) detection methods are costly and impractical for epidemic scenarios. Different immune-based assays have been reported for the detection and quantification of Ebola virus (EBOV) proteins. In particular, several monoclonal antibodies (mAbs) have been described that bind the capsid glycoprotein (GP) of EBOV GP. However, the currently available platforms for the design and production of full-length mAbs are cumbersome and costly. The use of antibody fragments, rather than full-length antibodies, might represent a cost-effective alternative for the development of diagnostic and possibly even therapeutic alternatives for EBOV.


RESULTS
We report the design and expression of three recombinant anti-GP mAb fragments in Escherichia coli cultures. These fragments contained the heavy and light variable portions of the three well-studied anti-GP full-length mAbs 13C6, 13F6, and KZ52, and are consequently named scFv-13C6, scFv-13F6, and Fab-KZ52, respectively. All three fragments exhibited specific anti-GP binding activity in ELISA experiments comparable to that of full-length anti-GP antibodies (i.e., the same order of magnitude) and they are easily and economically produced in bacterial cultures.


CONCLUSIONS
Antibody fragments might represent a useful, effective, and low cost alternative to full-length antibodies in Ebola related capture and diagnostics applications.
Centro de Biotecnología-FEMSA, Tecnológico de Monterrey at Monterrey, Monterrey, Nuevo León, México.
Luis Mario
LM
Rodríguez-Martínez
Centro de Biotecnología-FEMSA, Tecnológico de Monterrey at Monterrey, Monterrey, Nuevo León, México.
Alan Roberto
AR
Marquez-Ipiña
Centro de Biotecnología-FEMSA, Tecnológico de Monterrey at Monterrey, Monterrey, Nuevo León, México.
Felipe
F
López-Pacheco
Centro de Biotecnología-FEMSA, Tecnológico de Monterrey at Monterrey, Monterrey, Nuevo León, México.
Roberto
R
Pérez-Chavarría
Centro de Biotecnología-FEMSA, Tecnológico de Monterrey at Monterrey, Monterrey, Nuevo León, México.
Juan Carlos
JC
González-Vázquez
Centro de Biotecnología-FEMSA, Tecnológico de Monterrey at Monterrey, Monterrey, Nuevo León, México.
Everardo
E
González-González
Centro de Biotecnología-FEMSA, Tecnológico de Monterrey at Monterrey, Monterrey, Nuevo León, México; Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America; Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Grissel
G
Trujillo-de Santiago
Centro de Biotecnología-FEMSA, Tecnológico de Monterrey at Monterrey, Monterrey, Nuevo León, México.
César Alejandro
CA
Ponce-Ponce de León
Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America; Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Yu Shrike
YS
Zhang
Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America; Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Mehmet Remzi
MR
Dokmeci
Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America; Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, United States of America; Department of Physics, King Abdulaziz University, Jeddah, Saudi Arabia.
Ali
A
Khademhosseini
Centro de Biotecnología-FEMSA, Tecnológico de Monterrey at Monterrey, Monterrey, Nuevo León, México; Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America; Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Mario Moisés
MM
Alvarez
D000911:Antibodies, Monoclonal / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology*; D029043:Ebolavirus / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D006023:Glycoproteins / Q000276:immunology / Q000378:metabolism*; D019142:Hemorrhagic Fever, Ebola / Q000175:diagnosis* / Q000378:metabolism / Q000821:virology; D006801:Humans; D010446:Peptide Fragments / Q000276:immunology / Q000378:metabolism*; D011994:Recombinant Proteins / Q000276:immunology / Q000378:metabolism; D014759:Viral Envelope Proteins / Q000276:immunology / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D006023:Glycoproteins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D014759:Viral Envelope Proteins